Revealed: The spy who regulates neuroblastoma stem cells
Metrics: PDF 1102 views | HTML 1264 views | ?
Parvez Vora1, Chitra Venugopal1 and Sheila K. Singh1,2,3
1 McMaster Stem Cell and Cancer Research Institute, McMaster University, Hamilton, Canada
2 Department of Biochemistry and Biomedical Sciences, Faculty of Health Sciences, McMaster University, Hamilton, Canada
3 Department of Surgery, Faculty of Health Sciences, McMaster University, Hamilton, Canada
Sheila K. Singh, email:
Keywords: Spy1, neuroblastoma, CD133
Received: August 17, 2014 Accepted: December 01, 2014 Published: December 02, 2014
Neuroblastoma (NB), an embryonal tumour of the sympathetic nervous system, is thought to originate from undifferentiated neural crest cells and is known to exhibit extremely heterogeneous biological and clinical behaviors. Occurring in very young children, the median age at diagnosis is 17 months and it accounts for 10% of all pediatric cancer mortalities [1, 2]. The standard treatment regimen for patients with high-risk NB includes induction and surgery followed by isotretinoin or Accutane (13-cis retinoic acid) treatment, which is shown to induce terminal differentiation of NB cells . However, molecular regulators that maintain an undifferentiated phenotype in NB cells are still poorly understood.
Human cancer cells can arise from either stem/progenitor cells that fail to exit the cell cycle and differentiate, or from de-differentiated cells that have re-entered the cell cycle. A pre-requisite for differentiation is induction of cell cycle exit by the cell cycle regulators. One such cell cycle regulator, Speedy/RINGO (Spy1), was recently shown to maintain glioma tumour initiating cells (TICs) by regulating cell proliferation and stemness . Spy1, an activator of cyclin-dependant kinases (CDK), is known to mediate cell cycle progression and cell survival in response to DNA damage [5, 6]. In the recent issue of Oncoscience, researchers give a mechanistic insight into Spy1-mediated regulation of NB stem cell differentiation .
Interestingly, when human neuroblastoma SH-SY5Y cells were subjected to 13-cis-Retinoic Acid (RA)-induced differentiation, the endogenous transcript as well as protein levels of Spy1 deplete significantly. Moreover, Spy1 expression level was shown to correlate with decreased levels of neural stem cell maker Nestin and increased levels of neuronal differentiation marker GAP43. The kinase activity of CDK2, a downstream signaling mediator of Spy1, was also shown to decline concurrently with Spy1 expression.
Furthermore, using both shRNA knockdown and overexpression approaches, the authors demonstrate a significant functional contribution of Spy1 to self-renewal, proliferation and differentiation of NB cell lines (Figure 1a). Spy1 overexpressing cell lines failed to differentiate upon RA induction, continued proliferating and demonstrated enhanced self-renewal ability compared to the control cell line. Conversely, loss of Spy1 in NB cell lines lead to decreased cell proliferation and induced neuronal differentiation. The effect on Spy1 gain/loss of function in NB cells must be evaluated on in vivo tumour-forming mouse models before translating these exciting findings to the next level.
Numerous studies have shown that stemness in cancer is maintained in a hypoxic microenvironment. Growing NB cell lines as spheroid suspension cultures lead to increased expression of stem cell markers Oct4 and Bmi1 in Spy1-elevated cells. Providing a brief insight into the role of micro-environmental conditions and Spy1 functionality in regulating stemness, the authors underscore the importance of spheroids as 3D models of in vivo solid tumours.
The authors then go on to delineate the mechanism of Spy1 action on putative NB TICs, marked by CD133 positivity. A previous study reported that the intermediate type (I-type) NB cells have high expression of CD133 compared to other less tumorigenic subtypes of NB . However, a later study failed to detect CD133 expression in NB TICs . The authors here show no difference in self-renewal ability of CD133+ vs CD133- NB cells. Thus, it remains unclear whether CD133-expressing NB cells possess the defining properties of TICs. Nevertheless, CD133 is shown to mechanistically play a role in regulating NB tumorigenesis and proliferation by preventing differentiation . Here, the authors selectively knock down Spy1 in CD133+ NB cells and show a significant decline in sphere formation. But when Spy1 was overexpressed, the CD133- population showed enhanced self-renewal capacity (Figure 1b), accompanied by an increase in CD133 transcript levels. Is Spy1 indirectly regulating CD133 expression, which then blocks the differentiation of NB stem cells? These findings also suggest that Spy1 regulates clonogenicity of NB cells, possibly having a differential effect on CD133+ and CD133- populations. These findings could be substantiated by comparing the effects of Spy1 knockdown and overexpression in CD133+ and CD133- NB cell populations in parallel.
This research takes a step towards understanding the molecular regulation of NB TICs differentiation, the currently employed strategy to treat this dreadful tumour. Previous studies have shown that widespread differentiated NB tumours have a better prognosis than poorly differentiated ones [11, 12], an observation consistent with the CSC model in suggesting that undifferentiated NB cells drive tumour progression. This novel finding that Spy1, an atypical G1 phase regulator, is also a key suppresser of differentiation and a promoter of self-renewal of NB TICs, may yield more potent prognostic factors and druggable therapeutic targets for NB patients. Perhaps inhibition of Spy1 or its downstream signaling targets could contribute to less aggressive tumours and maybe even lead to new and improved therapies for high-risk NB patients in the clinic.
Figure 1: Spy1 regulates Neuroblastoma (NB) stem cells. (A) Upon RA-induced differentiation, Spy1 depletion caused decreased proliferation and increased differentiation, while Spy1 overexpression delayed differentiation and promoted proliferation in NB cell lines. (B) Knockdown of Spy1 in CD133+ NB stem cells resulted in decreased clonogenicity. When Spy1 was overexpressed in the CD133- NB subpopulation, there was a significant rise in the expression of stem cell markers and showed increased self-renewal property.
1. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP and Cohn SL. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol. 2005; 23:6459-6465.
2. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O’Leary M, Smith FO and Reaman GH. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010; 28:2625-2634.
3. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB and Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999; 341:1165-1173.
4. Lubanska D, Market-Velker BA, deCarvalho AC, Mikkelsen T, Fidalgo da Silva E and Porter LA. The cyclin-like protein Spy1 regulates growth and division characteristics of the CD133+ population in human glioma. Cancer Cell. 2014; 25:64-76.
5. Porter LA, Dellinger RW, Tynan JA, Barnes EA, Kong M, Lenormand JL and Donoghue DJ. Human Speedy: a novel cell cycle regulator that enhances proliferation through activation of Cdk2. J Cell Biol. 2002; 157:357-366.
6. Barnes EA, Porter LA, Lenormand JL, Dellinger RW and Donoghue DJ. Human Spy1 promotes survival of mammalian cells following DNA damage. Cancer Res. 2003; 63:3701-3707.
7. Lubanska D and Porter LA. The atypical cell cycle regulator Spy1 suppresses differentiation of the neuroblastoma stem cell population. Oncoscience. 2014; 1:336-348.
8. Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo HF, Biedler JL, Cheung NK and Ross RA. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia. 2004; 6:838-845.
9. Hansford LM, McKee AE, Zhang L, George RE, Gerstle JT, Thorner PS, Smith KM, Look AT, Yeger H, Miller FD, Irwin MS, Thiele CJ and Kaplan DR. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res. 2007; 67:11234-11243.
10. Takenobu H, Shimozato O, Nakamura T, Ochiai H, Yamaguchi Y, Ohira M, Nakagawara A and Kamijo T. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene. 2011; 30:97-105.
11. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV and Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999; 86:349-363.
12. Nitschke R, Smith EI, Shochat S, Altshuler G, Travers H, Shuster JJ, Hayes FA, Patterson R and McWilliams N. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. J Clin Oncol. 1988; 6:1271-1279.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.